PDCD1 and cancer: ICB-based cancer immunotherapies, notably the T cell immune checkpoint inhibitors anti-cytotoxic T lymphocyte associated protein 4 (CTLA-4) and the anti-programmed cell death protein 1 (PD-1), have provided durable clinical benefit in diverse cancer patients [4].